Morgan Stanley assumed coverage of Immunocore (IMCR) with an Equal Weight rating and $35 price target The firm remains positive on Kimmtrak sales, but believes sales expectations are largely reflected in the shares, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings: Pioneering HIV Cure with Promising Phase 1 STRIVE Trial Results
- Immunocore Reports 2024 Growth and Strategic Advances
- Immunocore’s Strategic Expansion and Robust Pipeline Drive Buy Rating
- Immunocore Holdings: Positive Earnings Call Highlights Growth
- Immunocore price target lowered to $85 from $88 at Oppenheimer